References
- Bender, R., Koch, A., Skipka, G., Kaiser, T., Lange, S. (2010). No inconsistent trial assessments by NICE and IQWiG: different assessment goals lead to different assessment results regarding subgroup analyses. Journal of Clinical Epidemiology 63:1305–1307.
- Brookes, S., Whitely, E., Egger, M., Smith, G., Mulheran, P., Peters, T. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 57:229–236.
- CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 348:1329–1339.
- Dent, L., Raftery, J. (2011). Treatment success in pragmatic randomised controlled trials: a review of trials funded by the UK Health Technology Assessment programme. Trials 12: Article 109.
- Djulbegovic, B., Kumar, A., Miladinovic, B., Reljic, T., Galeb, S., Mhaskar, A., Mhaskar, R., Hozo, I., Tu, D., Stanton, H., et al. (2013). Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. Plos One 8: Article e58711.
- Djulbegovic, B., Kumar, A., Soares, H., Hozo, I., Bepler, G., Clarke, M., Bennett, C. (2008). Treatment success in cancer. Archives of Internal Medicine 168:632–642.
- European Medicines Agency. (2000). Points to consider on validity and interpretation of meta-analyses, and one pivotal study. Released in October 2000: http://www.emAdda.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003659.pdf.
- European Medicines Agency. (2010). Concept paper on the need for a guideline on the use of subgroup analyses in randomised controlled trials. Released on 22-04-2010: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090116.pdf.
- European Medicines Agency. (2014). Draft guideline on the investigation of subgroups in confirmatory clinical trials. Released in January 2014: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500160523.pdf.
- FDA Advisory Committee. (1997). 82nd meeting of the cardiovascular and renal drugs committee. Released on 24-10-1997: http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3338t2.pdf.
- Food and Drug Administration. (1998). Guidance for industry: Providing clinical evidence of effectiveness for human drug and biological products. Released in May 1998: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf.
- Hasford, J., Bramlage, P., Koch, G., Lehmacher, W., Einhaeupl, K., Rothwell, P. (2010). Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: Standards for the performance and interpretation of subgroup analyses are needed. Journal of Clinical Epidemiology 63:1298–1304.
- ICH Steering Committee. (1999). Statistical principles for clinical trials (ICH E9). Statistics in Medicine 18:1905–1942.
- Ikeda, K., Bretz, F. (2010). Sample size and proportion of Japanese patients in multiregional trials. Pharmaceutical Statistics 9:207–216.
- IQWiG. (2006). Final report plan for the evaluation: “Clopidogrel versus acetyl-salicylic acid in the secondary prevention of vascular events”. Released in January 2006: http://www.iqwig.de/download/A04-1A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf.
- Jones, H., Ohlssen, D., Neuenschwander, B., Racine, A., Branson, M. (2011). Bayesian models for subgroup analysis in clinical trials. Clinical Trials 8:129–143.
- JPFSB (2007). Japanese Pharmaceutical and Food Safety Bureau: Basic principles on global clinical trials. Released on 28-09-2007: http://www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf.
- Kumar, A., Soares, H., Wells, R., Clarke, M., Hozo, L., Bleyer, A., Reaman, G., Chalmers, I., Djulbegovic, B. (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children’s Oncology Group. British Medical Journal 331:1295–1298B.
- Maggioni, A., Darne, B., Atard, D., Abadie, E., Pitt, B., Zannad, F. (2007). FDA and CPMP rulings on subgroup analyses. Issues in Drug Development 107:97–102.
- Newcombe, R. (1998). Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 17:873–890.
- NICE. (2005). Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. Released in May 2005: www.nice.org.uk/nicemedia/pdf/TA090guidance.pdf.
- Paget, M., Chuang-Stein, C., Fletcher, C., Reidd, C. (2011). Subgroup analyses of clinical effectiveness to support health technology assessments. Pharmaceutical Statistics 10:532–538.
- Pocock, S., Assmann, S., Enos, L., Kasten, L. (2002). Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in Medicine 21:2917–2930.
- Pocock, S., Calvo, G., Marrugat, J., Prasad, K., Tavazzi, L., Wallentin, L., Zannad, F., Garcia, A. (2013). International differences in treatment effect: do they really exist and why? European Heart Journal 34:1846–1852.
- Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of The American Medical Association 266:93–98.